Status:
COMPLETED
Sublingual Methadone for the Management of Cancer Breakthrough Pain
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Calgary Health Region
Conditions:
Cancer
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.
Detailed Description
This is a dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.
Eligibility Criteria
Inclusion
- \> 18 years of age
- Experiences episodes of breakthrough pain which respond to opioid therapy
- Controlled baseline pain
- Cognitive status sufficient for accurate completion of assessment form
- Willing to provide written informed consent
- Ability to hold a volume of 1 cc of water under the tongue for 5 minutes
Exclusion
- Currently or has received methadone during the previous week
- Recent history of substance abuse
- Severe respiratory impairment or other contraindications to opioids
- Recently received therapies that had the potential to alter pain intensity or response to analgesics
- Symptomatic anemia
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00125294
Start Date
September 1 2003
End Date
January 1 2007
Last Update
September 25 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.